Evidence map›Paper›PMID 38034269›Full record

ArticleCureus2023

Effects of Pharmacotherapy for the Treatment of Obesity in an Urban, Safety-Net Population.

Eric K Kim, Nancy K Hills, Zoe Cheng, Caroline Tucker, Maria Gutierrez, Diana Alba, Elizabeth Murphy, Sarah Kim

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Eric K KimDepartment of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, USA.
Nancy K HillsDepartment of Neurology, University of California San Francisco, San Francisco, USA.
Zoe ChengDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, USA.
Caroline TuckerDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, USA.
Maria GutierrezDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, USA.
Diana AlbaDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, USA.
Elizabeth MurphyDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, USA.
Sarah KimDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, USA.
University of California, San Francisco · USUniversity of San Francisco · USSan Francisco General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect of common weight loss pharmacotherapies among low-income, racially diverse adult patients at an urban safety-net weight management clinic.

methodsOur retrospective review from 2015 to 2019 examined patients who took either GLP-1 analog (GL) or phentermine/topiramate (PT) for ≥90 days and patients who exclusively pursued non-pharmacologic treatment for comparison. Changes in weight, blood pressure, and hemoglobin A1c at 1-year follow-up were reported.

resultsWe analyzed 22 GL and 26 PT patients and included 40 patients who pursued only lifestyle modifications (LM). All three groups achieved significant weight loss at one year: GL -3.69 (interquartile range (IQR): -11.0, -1.77) kg (p=0.0004), PT -7.01 (IQR: -13.4, -1.45) kg (p<0.001), and LM -3.01 (IQR: -6.81, 1.13) kg (p=0.005). There was no significant difference in the median weight loss (p=0.11) between the three groups. We observed no significant changes in systolic blood pressure but saw a significant change of -0.75 in hemoglobin A1c (IQR: -1.35, -0.25) (p=0.01) among patients with diabetes in the GL group.

conclusionsOur real-world applications of GLP-1 and phentermine/topiramate suggest that both are effective weight loss medication regimens in low-socioeconomic status patients.

Indexed as

glp-1obesitypharmacotherapyphenterminetopiramateweight loss

Identifiers

PMID38034269
PMCPMC10682737
OpenAlexW4388006507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.